🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT05295810
Recruiting Not applicable

Hypercapnia in Orthostatic Hypotension

NCT05295810 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2022-03-01
Last updated
2026-05-05

Condition(s) studied

Orthostatic HypotensionNeurogenic Orthostatic Hypotension

Investigational drug(s) / intervention(s)

Sequential Gas Delivery

Sequential Gas Delivery: Sequential Gas Delivery will be controlled using the RespirAct™ system (Thornhill Research Inc., Toronto, Canada)

Study summary

The Autonomic (or "automatic") Nervous System (ANS) regulates internal processes, including control of heart rate and blood pressure (BP). When someone stands, and gravity tries to pull blood away from the brain, the ANS works to maintain BP and brain blood flow. Neurogenic Orthostatic Hypotension (NOH) occurs when our "fight-or-flight" part ("sympathetic") of the ANS fails. BP can drop a lot when upright, reducing blood flow and oxygen delivery to the brain, and this can cause symptoms of light-headedness, nausea, and fainting.

One solution to help counter the effects of NOH may be to increase sympathetic activity by breathing higher levels of carbon dioxide. In healthy volunteers, small increases in the amount of inhaled carbon dioxide has been shown to increase BP in the upright position, and this improves symptoms!

The objectives of the current study are to apply carbon dioxide in patients with NOH and healthy controls to: (a) evaluate the effects of breathing carbon dioxide on BP and brain blood flow, and (b) determine if a device that increases carbon dioxide while standing will work as a new therapy

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥18 years * Male and Female * Non - smokers. * Able and willing to provide informed consent. * Ability to travel to Libin Cardiovascular Institute Autonomic Testing Lab at the University of Calgary, Calgary, AB. Exclusion Criteria: * Medical therapies or medications which could interfere with testing of autonomic function * Participants with somatization or severe anxiety symptoms will be excluded * Pregnant or breast-feeding females * Inability to tolerate mask for the duration of the study * Subjects who require portable oxygen at rest or with exercise * Subjects with chronic heart failure or severe pulmonary disease who are unable to climb one flight of stairs due to shortness of breath. * Presence of failure of other organ systems or systemic illness that can affect autonomic function or the participant's ability to cooperate. These include: dementia, alcohol and/or drug abuse, cerebrovascular disease, kidney or liver disease, surgical procedures where the nerves of the sympathetic nervous system have been cut. * Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Calgary Calgary Alberta Recruiting

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05295810 on ClinicalTrials.gov ↗ ← All trials in Canada